Merck: Number of Employees 2012-2026 | MRK
Interactive chart of Merck (MRK) annual worldwide employee count from 2012 to 2026.
- Merck total number of employees in 2025 was 75,000, a 0% decline from 2024.
- Merck total number of employees in 2024 was 75,000, a 4.17% increase from 2023.
- Merck total number of employees in 2023 was 72,000, a 4.35% increase from 2022.
- Merck total number of employees in 2022 was 69,000, a 1.47% increase from 2021.
| Merck Annual Employee Count | |
|---|---|
| 2025 | 75,000 |
| 2024 | 75,000 |
| 2023 | 72,000 |
| 2022 | 69,000 |
| 2021 | 68,000 |
| 2020 | 74,000 |
| 2019 | 71,000 |
| 2018 | 69,000 |
| 2017 | 69,000 |
| 2016 | 68,000 |
| 2015 | 68,000 |
| 2014 | 70,000 |
| 2013 | 76,000 |
| 2012 | 83,000 |
| 2011 | 86,000 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $370.890B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| Johnson & Johnson (JNJ) | United States | $663.276B | 25.34 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Pfizer (PFE) | United States | $162.156B | 9.33 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |
| Innoviva (INVA) | United States | $1.541B | 5.27 |